Results 101 to 110 of about 714 (147)
Some of the next articles are maybe not open access.
NeuroReport, 1997
Systemic administration of the 5-HT1A receptor agonist 8-OH-2-(di-n-propylamino)-tetralin (8-OH-DPAT; 0.3 mg/kg, s.c.) was used to explore the effects of activation of 5-HT1A receptors on expression of mRNA coding for 5-HT1A receptor, tryptophan hydroxylase (TPH) and galanin in the ascending raphe nuclei. 8-OH-DPAT increased the hybridization signal of
H, Razani +4 more
openaire +2 more sources
Systemic administration of the 5-HT1A receptor agonist 8-OH-2-(di-n-propylamino)-tetralin (8-OH-DPAT; 0.3 mg/kg, s.c.) was used to explore the effects of activation of 5-HT1A receptors on expression of mRNA coding for 5-HT1A receptor, tryptophan hydroxylase (TPH) and galanin in the ascending raphe nuclei. 8-OH-DPAT increased the hybridization signal of
H, Razani +4 more
openaire +2 more sources
Life Sciences, 1995
The effects of two putative 5-HT1A antagonists, 4-(2'-methoxyphenyl)-1- [2'-[N-(2"-pyridinyl)-p-iodobenzamido]ethyl]piperazine (p-MPPI) and 4-(2'-methoxyphenyl)-1-[2'-[N-(2"-pyridinyl)-p- fluorobenzamido]ethyl]piperazine (p-MPPF), were examined in vivo in two tests of postsynaptic 5-HT1A receptor activation, hypothermia and reciprocal forepaw treading,
R J, Thielen, A, Frazer
openaire +2 more sources
The effects of two putative 5-HT1A antagonists, 4-(2'-methoxyphenyl)-1- [2'-[N-(2"-pyridinyl)-p-iodobenzamido]ethyl]piperazine (p-MPPI) and 4-(2'-methoxyphenyl)-1-[2'-[N-(2"-pyridinyl)-p- fluorobenzamido]ethyl]piperazine (p-MPPF), were examined in vivo in two tests of postsynaptic 5-HT1A receptor activation, hypothermia and reciprocal forepaw treading,
R J, Thielen, A, Frazer
openaire +2 more sources
Treatment of cerebellar ataxia with 5‐HT1A agonist
The Cerebellum, 2005Effective, pharmacologic approaches to the treatment of cerebellar ataxia are lacking or inadequate. We recently reported preliminary evidence that tandospirone citrate (tandospirone), a 5-HT1A agonist, improved cerebellar ataxia in patients with Machado-Joseph disease (MJD). In the course of that study, we found that such treatment also alleviated the
Asako, Takei +3 more
openaire +2 more sources
The 5-HT1A receptor: an overview of recent advances
Neurochemical Research, 1991Progress in the field of neuronal receptor research has accelerated during the last few years due to developments in pharmacology and molecular biology. This is particularly true in the case of the serotonin 5-HT1A receptor. In 1983 the very selective, high affinity 5-HT1A agonist 8-OH-DPAT was developed which allowed the pharmacology and distribution ...
S, el Mestikawy +4 more
openaire +2 more sources
Antipeptide antibodies against the 5-HT1A receptor
Journal of Chemical Neuroanatomy, 1992The availability of the primary amino acid sequence for a large number of molecules provides a fruitful opportunity for their cellular localization by utilizing the procedure of antipeptide antibody formation. This procedure permits a synthetic peptide sequence to be attached to a carrier molecule for the purpose of inoculating an animal to raise ...
E C, Azmitia +5 more
openaire +2 more sources
Antiemetic effects of 5-HT1A agonists in the pigeon
Pharmacology Biochemistry and Behavior, 1994Ditolyguanidine (DTG) induced a dose-dependent emetic response in pigeons, with 100% of the birds vomiting after 5.6 mg/kg. Retching and vomiting originally induced by DTG could be conditioned to the test situation. Both the unconditioned and conditioned emetic responses were dose-dependently blocked by 8-hydroxy-(di-n-propylamino)tetralin (8-OH-DPAT ...
M C, Wolff, J D, Leander
openaire +2 more sources
1991
Brain 5-HT receptors have been classified in at least six subtypes (5-HT1A, 1B, 1C, 1D, 2 AND 3; Peroutka, 1988), among which the 5-HT1A subtype has been the focus of intense research during the last few years. This receptor type is located both presynaptically on the 5-HT cell bodies (somatodendritic receptors), predominantly in the dorsal and median ...
J. De Vry +4 more
openaire +1 more source
Brain 5-HT receptors have been classified in at least six subtypes (5-HT1A, 1B, 1C, 1D, 2 AND 3; Peroutka, 1988), among which the 5-HT1A subtype has been the focus of intense research during the last few years. This receptor type is located both presynaptically on the 5-HT cell bodies (somatodendritic receptors), predominantly in the dorsal and median ...
J. De Vry +4 more
openaire +1 more source
Anticonflict effects of the 5-HT1A compound flesinoxan
Journal of Psychopharmacology, 1989The new phenylpiperazine derivative flesinoxan, a potent and selective serotonin 1A (5-HT 1A ) agonist, was examined under a procedure that has proved to be a reliable and sensitive method for detecting novel anxiolytic drugs believed to produce their ...
J E, Barrett +3 more
openaire +2 more sources
5-HT1A receptor antagonists and lordosis behavior
Neuropharmacology, 1996In proestrous rats, serotonin 1A (5-HT1A) receptor agonists inhibit lordosis behavior within 5-15 min following infusion into the ventromedial nucleus of the hypothalamus (VMN). In the present report, the lordosis-inhibiting effects of the 5-HT1A agonist [(+/-) 8-hydroxy-2- (di-n-propylamino) tetralin) (8-OH-DPAT] were shown to be attenuated with 5 ...
L, Uphouse +3 more
openaire +2 more sources
Agonistic Properties of Cannabidiol at 5-HT1a Receptors
Neurochemical Research, 2005Cannabidiol (CBD) is a major, biologically active, but psycho-inactive component of cannabis. In this cell culture-based report, CBD is shown to displace the agonist, [3H]8-OH-DPAT from the cloned human 5-HT1a receptor in a concentration-dependent manner.
Ethan B, Russo +3 more
openaire +2 more sources